NEWS &
PRESS
RELEASES
Read our latest announcements and media
coverage as we continue building a stronger,
more connected healthcare ecosystem in LATAM.
Press Releases
SteinCares Strengthens its Onco-Hematology Portfolio with the Introduction of Spectrila® in Brazil
São Paulo, Brazil, March 26th 2026 – SteinCares, a leading specialty healthcare company in Latin America, today announced Brazil’s Agencia Nacional de Vigilância Sanitária, ANVISA, has approved the registration transfer for Spectrila®, an essential recombinant E. coli asparaginase biologic used in the treatment of Acute Lymphoblastic Leukemia (ALL). SteinCares will now
SteinCares and Shilpa Biologicals Strike into licensing agreement to Expand Access to Biosimilars Across Latin America
San Jose, Costa Rica and Karnataka, India — February 24th, 2026 — SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd., a fully integrated biopharmaceutical company and subsidiary of Shilpa Medicare Limited, announce a strategic licensing agreement to commercialize a biosimilar across Latin America. Under the agreement, SteinCares
SteinCares Earns AA Rating from Moody’s, Reflecting Strong Financial Profile, Operational Excellence, and Robust Governance
San Jose, Costa Rica, January 19th, 2026 — SteinCares announced today that Moody’s Investors Service has assigned the company an AA credit rating with Stable outlook, highlighting its solid financial position, resilient business model, and disciplined operational execution across Latin America’s pharmaceutical sector. The rating recognizes SteinCares’ robust cash flow generation,
SteinCares Expands its Portfolio in Brazil with Monofer®
São Paulo, Brazil – December 8th 2025 SteinCares, a leading specialty healthcare company in Latin America, today announced the addition of Monofer® (iron isomaltoside 1000) into its Brazilian portfolio, following the recent transfer of commercialization rights. With this milestone, SteinCares strengthens its presence in Brazil and expands access to innovative treatments
SteinCares Opens New Facility in Costa Rica to Strengthen Access to Specialty Healthcare Across Latin America
San Jose, Costa Rica – August 26, 2025 – In line with its purpose to create healthcare opportunities across Latin America, SteinCares today announced the opening of its new secondary packaging facility in Costa Rica. This strategic investment is a milestone for SteinCares’ regional consolidation and will support its expansion and
SteinCares Enters the Mexican Market Through a Strategic Joint Venture with Laboratorios Carnot
San Jose, Costa Rica, July 28, 2025. SteinCares, a leading specialty healthcare company in Latin America operating in over 30 countries, today announced its official entry into the Mexican market through a strategic joint venture with Laboratorios Carnot, a leading Mexican pharmaceutical company with more than 80 years of experience in
SteinCares and Shilpa Biologicals Strike into licensing agreement to Expand Access to Biosimilars Across Latin America
San Jose, Costa Rica and Karnataka, India — February 24th, 2026 — SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd., a fully integrated biopharmaceutical company and subsidiary of Shilpa Medicare Limited, announce a strategic licensing agreement to commercialize a biosimilar across Latin America. Under the agreement, SteinCares
SteinCares Earns AA Rating from Moody’s, Reflecting Strong Financial Profile, Operational Excellence, and Robust Governance
San Jose, Costa Rica, January 19th, 2026 — SteinCares announced today that Moody’s Investors Service has assigned the company an AA credit rating with Stable outlook, highlighting its solid financial position, resilient business model, and disciplined operational execution across Latin America’s pharmaceutical sector. The rating recognizes SteinCares’ robust cash flow generation,
SteinCares Strengthens its Onco-Hematology Portfolio with the Introduction of Spectrila® in Brazil
São Paulo, Brazil, March 26th 2026 – SteinCares, a leading specialty healthcare company in Latin America, today announced Brazil’s Agencia Nacional de Vigilância Sanitária, ANVISA, has approved the registration transfer for Spectrila®, an essential recombinant E. coli asparaginase biologic used in the treatment of Acute Lymphoblastic Leukemia (ALL). SteinCares will now
SteinCares on the News
PRNewswire
Forbes
Media Contact
Victoria Carrillo
Corporate Communications Manager